ClinicalTrials.gg
CompletedNCT03417518Updated Feb 9, 2018

Effects of Anesthesia With Propofol Versus Desflurane in Obese Patients

A Phase 4 interventional study of Desflurane Inhalant Product and Propofol in Anesthesia and Obesity, sponsored by Centre Hospitalier Universitaire Saint Pierre. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-02-09.

Sponsored by Centre Hospitalier Universitaire Saint Pierre · Phase 4, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jan 2015, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing propofol in Obesity — 1 open to participants now, 1 under way, none of them phase 3. Propofol · Obesity.

Enrollment
7th of 12
40 · median 55
Started
2015
the only one that year
Phase 4
5 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Centre Hospitalier Universitaire Saint Pierre

Among the 12 studies testing propofol in Obesity, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 4, and was the 8th registered.

Obesity

11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 12 studies testing propofol in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About propofol

Propofol: first FDA approval 1989 (DIPRIVAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing propofol in Obesity, or all of them as a file.
02

Study summary

Evaluate the effects of propofol compared with desflurane on oxidative stress and inflammation markers in obese patients undergoing scheduled bariatric surgery.

Read the detailed description

Obese patients have a high level of oxidative stress and inflammation activity. Desflurane is an anesthetic gas often used for obese patients. Propofol, another anesthetic agent, has shown an antioxidant property. The aim of the study is to compare the effects of propofol with desflurane on oxidative stress and inflammation markers in obese patients.

03

Conditions studied

  • Anesthesia
  • Obesity

Browse trials for

Keywords

  • Oxidative stress
  • Bariatric surgery
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) >35
  • scheduled gastric by pass surgery
  • (ASA) \<III

Exclusion criteria

Exclusion Criteria:

  • Allergic to anesthesia agent
  • patient refusal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Desflurane Inhalant Product Group

    general anesthesia with desflurane

    Drug: Desflurane Inhalant Product

  • Experimental
    Propofol Group

    general anesthesia with propofol

    Drug: Propofol

Interventions

  • General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane

    Also known as: Suprane

  • General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Malondialdehyde (MDA) level in blood sample

    Plasma MDA level is measured as an oxidative stress marker before the surgery, at 1 hour, 2 hours, 24 hours post-surgical incision.

    Time frame: up to 24 hours post bariatric surgery

Secondary outcomes

  1. C-Reactive Protein (CRP) in blood sample

    Plasma CRP level is measured as an inflammation marker before the surgery, at 1 hour, 2 hours, 24 hours post-surgical incision.

    Time frame: up to 24 hours post bariatric surgery

  2. Monocyte level in blood sample

    Monocyte level is measured as an inflammation marker before the surgery, at 1 hour, 2 hours, 24 hours post-surgical incision.

    Time frame: up to 24 hours post bariatric surgery

  3. Pain assessed by Visual Analog Scale (VAS)

    Pain level is determined at 2 hours, 24 hours and 48 hours post-surgical incision. Visual analog pain score (scale = 0 no pain; 10= worst pain imaginable)

    Time frame: up to 48 hours after surgery

  4. Side-effects (nausea, vomiting, somnolence, respiratory depression)

    Evaluation at 2 hours, 24 hours and 48 hours post-surgical incision

    Time frame: up to 48 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, Palicka V. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med. 2008;46(4):499-505. doi: 10.1515/CCLM.2008.096. PubMed 18298345 ↗
  • Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):316-28. doi: 10.1016/j.numecd.2005.05.003. PubMed 16054557 ↗
  • Murphy PG, Myers DS, Davies MJ, Webster NR, Jones JG. The antioxidant potential of propofol (2,6-diisopropylphenol). Br J Anaesth. 1992 Jun;68(6):613-8. doi: 10.1093/bja/68.6.613. PubMed 1319189 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Oct 2015, 9 months.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 9 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Jan 31, 2018
StartActual
Jan 2015
Primary completionActual
Oct 2015
CompletionActual
Sep 2016
Last update
Feb 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03417518
Lead sponsor
Centre Hospitalier Universitaire Saint Pierre
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Jan 2015
Primary completion
Oct 2015
Completion
Sep 2016
Last update
Feb 9, 2018

Study contacts

Panayota Kapessidou
study director · University Hospital Saint-Pierre (CHU Saint-Pierre), Universite libre de Bruxelles (ULB)
Livia Di Marco, doctor
principal investigator · University Hospital Saint-Pierre (CHU Saint-Pierre)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion